Can monoamine-based therapies be improved?

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 2, 2002, Pages 14-18

  Demitrack, Mark A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; FLUOXETINE; MONOAMINE DERIVATIVE; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CONFERENCE PAPER; DEPRESSION; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; REMISSION;

ADRENERGIC BETA-ANTAGONISTS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; HUMANS; RECEPTORS, BIOGENIC AMINE; THIOPHENES; TREATMENT OUTCOME;

EID: 0036194104     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
2. Definition and epidemiology of treatment-resistant depression
3. Do some antidepressants work faster than others?
4. Lithium carbonate augmentation of antidepressant treatment: An effective prescription for treatment-refractory depression
5. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
6. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
7. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial
8. Pindolol augmentation of treatment-resistant depressed patients
9. Pindolol augmentation of antidepressants: A review and rationale
10. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: A dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans
11. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan
12. Use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders
13. Biochemical effects of antidepressant treatment: Studies of monoamine metabolites in cerebrospinal fluid and platelet [3H]imipramine binding
14. Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine
15. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
16. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression
17. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report
18. Citalopram: Clinical effect profile in comparison with clomipramine: A controlled multicenter study
19. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder
20. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression
21. Paroxetine in the treatment of melancholia and severe depression
22. Milnacipran and selective serotonin reuptake inhibitors in major depression
23. Amithptyline v the rest: Still the leading antidepressant after 40 years of randomised controlled trials
24. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
25. Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies
26. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
27. Evidence of the dual mechanisms of action of venlafaxine
28. Effexor (venlafaxine)
29. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients
30. Safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database
31. Efficacy and safety of duloxetine treatment of major depression
32. Open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder
33. LY248686, a new inhibitor of serotonin and norepinephrine reuptake
34. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex
35. Affinity of duloxetine and venlafaxine for 5-HT and norepinephrine transporters